drugset / Trial / NCT05779514

Effect of Mirabegron on Promoting Brown Adipose Tissue Activation

NCT05779514

NaSingle-groupOpen-labelTreatment

Summary

In previous preclinical studies, our group found that Mirabegron, a clinical drug, could activate brown adipose tissue and inhibit tumor growth in tumour-bearing mice.Investigators look forward to further evaluating the effect of Mirabegron-mediated brown adipose tissue activation, so as to provide new drug applications for clinical cancer prevention and treatment

Timeline

Start
2022-08-18
Primary completion
2023-12-31
Completion
2023-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Mirabegron Other / unclassified 100 mg Oral
Subject Mirabegron Other / unclassified 200 mg Oral

Indications